ECSP12011624A - Composición Farmacéutica para un Inhibidor de Proteasa del Virus de la Hepatitis C. - Google Patents
Composición Farmacéutica para un Inhibidor de Proteasa del Virus de la Hepatitis C.Info
- Publication number
- ECSP12011624A ECSP12011624A EC2012011624A ECSP12011624A ECSP12011624A EC SP12011624 A ECSP12011624 A EC SP12011624A EC 2012011624 A EC2012011624 A EC 2012011624A EC SP12011624 A ECSP12011624 A EC SP12011624A EC SP12011624 A ECSP12011624 A EC SP12011624A
- Authority
- EC
- Ecuador
- Prior art keywords
- pharmaceutical composition
- hepatitis
- protease inhibitor
- virus protease
- virus
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dispersion Chemistry (AREA)
- Biophysics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Nutrition Science (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Se describe una composición farmacéutica de un inhibidor de proteasa del virus de la hepatitis C que es adecuada para administración oral a través de una cápsula rellena de líquidos semisólidos y métodos para usar esta composición para inhibir la replicación del virus de la hepatitis C (VHC) y para el tratamiento de una infección por VHC. La composición farmacéutica líquida o semisólida de la presente invención comprende un compuesto de fórmula I o una sal farmacéuticamente aceptable del mismo, junto con uno o más lípidos y tensoactivos hidrófilos farmacéuticamente aceptables.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22350709P | 2009-07-07 | 2009-07-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP12011624A true ECSP12011624A (es) | 2012-02-29 |
Family
ID=43245003
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2012011624A ECSP12011624A (es) | 2009-07-07 | 2012-01-26 | Composición Farmacéutica para un Inhibidor de Proteasa del Virus de la Hepatitis C. |
Country Status (35)
| Country | Link |
|---|---|
| US (1) | US9034831B2 (es) |
| EP (1) | EP2451438B8 (es) |
| JP (1) | JP5607736B2 (es) |
| KR (1) | KR101685941B1 (es) |
| CN (1) | CN102470103B (es) |
| AP (1) | AP2011005979A0 (es) |
| AR (1) | AR077393A1 (es) |
| AU (1) | AU2010270783B2 (es) |
| BR (1) | BR112012000287B8 (es) |
| CA (1) | CA2767692C (es) |
| CL (1) | CL2012000054A1 (es) |
| CO (1) | CO6480980A2 (es) |
| DK (1) | DK2451438T3 (es) |
| EA (1) | EA023433B1 (es) |
| EC (1) | ECSP12011624A (es) |
| ES (1) | ES2464367T3 (es) |
| GE (1) | GEP20146016B (es) |
| HR (1) | HRP20140445T1 (es) |
| IL (1) | IL216098A (es) |
| MA (1) | MA33491B1 (es) |
| ME (1) | ME01718B (es) |
| MX (1) | MX2011013824A (es) |
| MY (1) | MY154683A (es) |
| NZ (1) | NZ596928A (es) |
| PE (1) | PE20120322A1 (es) |
| PL (1) | PL2451438T3 (es) |
| PT (1) | PT2451438E (es) |
| RS (1) | RS53209B (es) |
| SG (1) | SG177569A1 (es) |
| SI (1) | SI2451438T1 (es) |
| TN (1) | TN2012000009A1 (es) |
| TW (1) | TWI490216B (es) |
| UA (1) | UA104195C2 (es) |
| UY (1) | UY32760A (es) |
| WO (1) | WO2011005646A2 (es) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010033443A1 (en) * | 2008-09-17 | 2010-03-25 | Boehringer Ingelheim International Gmbh | Combination of hcv ns3 protease inhibitor with interferon and ribavirin |
| MA33491B1 (fr) | 2009-07-07 | 2012-08-01 | Boehringer Ingelheim Int | Composition pharmaceutique pour un inhibiteur de protease virale de l'hépatite c |
| NZ598465A (en) | 2009-10-30 | 2013-10-25 | Boehringer Ingelheim Int | Dosage regimens for hcv combination therapy comprising bi201335, interferon alpha and ribavirin |
| BR112013007423A2 (pt) | 2010-09-30 | 2016-07-12 | Boehringer Ingelheim Int | terapia combinada no que diz respeito ao tratamento da infecção por hcv |
| US8957203B2 (en) | 2011-05-05 | 2015-02-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8691757B2 (en) | 2011-06-15 | 2014-04-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
| GB2515942A (en) | 2011-10-21 | 2015-01-07 | Abbvie Inc | Combination treatment (e.g. with ABT-072 or ABT-333) of DAAs for use in treating HCV |
| PT107894A (pt) | 2011-10-21 | 2014-10-31 | Abbvie Inc | Métodos para o tratamento de hcv compreendendo pelo menos dois agentes antivirais de actuação directa, ribavirina, mas não interferão. |
| US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
| AU2013208024A1 (en) | 2012-01-12 | 2014-07-10 | Boehringer Ingelheim International Gmbh | Stabilized pharmaceutical formulations of a potent HCV inhibitor |
| WO2013137869A1 (en) | 2012-03-14 | 2013-09-19 | Boehringer Ingelheim International Gmbh | Combination therapy for treating hcv infection in an hcv-hiv coinfected patient population |
| WO2013147750A1 (en) | 2012-03-27 | 2013-10-03 | Boehringer Ingelheim International Gmbh | Oral combination therapy for treating hcv infection in specific patient sub-population |
| WO2013147749A1 (en) | 2012-03-27 | 2013-10-03 | Boehringer Ingelheim International Gmbh | Oral combination therapy for treating hcv infection in specific patient subgenotype populations |
| JP2015512900A (ja) | 2012-03-28 | 2015-04-30 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 特別な患者の遺伝子亜型分集団のｈｃｖ感染症を治療するための併用療法 |
| MX360452B (es) | 2012-10-19 | 2018-11-01 | Bristol Myers Squibb Co | Inhibidores del virus de la hepatitis c. |
| US9643999B2 (en) | 2012-11-02 | 2017-05-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| EP2914613B1 (en) | 2012-11-02 | 2017-11-22 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| EP2914598B1 (en) | 2012-11-02 | 2017-10-18 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| US9409943B2 (en) | 2012-11-05 | 2016-08-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| JP6342922B2 (ja) | 2013-03-07 | 2018-06-13 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｃ型肝炎ウイルス阻害剤 |
| WO2014138374A1 (en) | 2013-03-08 | 2014-09-12 | Boehringer Ingelheim International Gmbh | Oral combination therapy for treating hcv infection in specific patient sub-population |
| CA2903831A1 (en) * | 2013-03-15 | 2014-09-25 | Boehringer Ingelheim International Gmbh | Solid oral dosage formulation of hcv inhibitor in the amorphous state |
| EP2899207A1 (en) | 2014-01-28 | 2015-07-29 | Amikana.Biologics | New method for testing HCV protease inhibition |
| US11192914B2 (en) | 2016-04-28 | 2021-12-07 | Emory University | Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto |
| EP3959240A1 (en) | 2019-04-24 | 2022-03-02 | Sanofi Biotechnology | Methods of diagnosis and treatment of rheumatoid arthritis |
| AU2020288561A1 (en) | 2019-06-04 | 2021-12-23 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for treating pain in subjects with rheumatoid arthritis |
| CN114641485A (zh) | 2020-04-05 | 2022-06-17 | 辉瑞大药厂 | 用于治疗covid-19的化合物和方法 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI65914C (fi) | 1978-03-07 | 1984-08-10 | Sandoz Ag | Foerfarande foer framstaellning av farmaceutiska kompositionerinnehaollande cyklosporin a |
| US5342625A (en) | 1988-09-16 | 1994-08-30 | Sandoz Ltd. | Pharmaceutical compositions comprising cyclosporins |
| IL102236A0 (en) | 1991-06-27 | 1993-01-14 | Ltt Inst Co Ltd | Topical preparations containing cyclosporin |
| US5329976A (en) | 1991-12-09 | 1994-07-19 | Habley Medical Technology Corporation | Syringe-filling and medication mixing dispenser |
| GB9208712D0 (en) | 1992-04-22 | 1992-06-10 | Sandoz Ltd | Pharmaceutical compositions containing cyclosporin derivates |
| ES2308955T5 (es) | 1993-09-28 | 2012-04-03 | R.P. Scherer Gmbh | Fabricación de cápsulas de gelatina blanda |
| JPH11505257A (ja) | 1995-05-19 | 1999-05-18 | アボツト・ラボラトリーズ | 親油性薬物の自己乳化性製剤 |
| US5993858A (en) | 1996-06-14 | 1999-11-30 | Port Systems L.L.C. | Method and formulation for increasing the bioavailability of poorly water-soluble drugs |
| DK0989851T3 (da) * | 1997-07-29 | 2003-01-27 | Upjohn Co | Selvemulgerende formulering indeholdende sure lipofile forbindelser |
| PT999826E (pt) * | 1997-07-29 | 2004-09-30 | Upjohn Co | Formulacao auto-emulsionante para compostos lipofilos |
| ES2174462T3 (es) | 1997-07-29 | 2002-11-01 | Upjohn Co | Formulacion autoestimulante para compuestos lipofilos. |
| US6323180B1 (en) | 1998-08-10 | 2001-11-27 | Boehringer Ingelheim (Canada) Ltd | Hepatitis C inhibitor tri-peptides |
| US6294192B1 (en) | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
| US6652880B1 (en) | 1999-04-01 | 2003-11-25 | R.P. Scherer Technologies, Inc. | Oral pharmaceutical compositions containing long-chain triglycerides and liphophilic surfactants |
| SE0000773D0 (sv) * | 2000-03-08 | 2000-03-08 | Astrazeneca Ab | New formulation |
| GB0008785D0 (en) | 2000-04-10 | 2000-05-31 | Novartis Ag | Organic compounds |
| AU2002351169B2 (en) | 2001-11-26 | 2007-09-20 | Intas Pharmaceuticals Limited | Method for preparing and using polyoxyethylated castor oil in pharmaceutical compositions |
| US6828301B2 (en) | 2002-02-07 | 2004-12-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for hepatitis C viral protease inhibitors |
| CZ294371B6 (cs) | 2002-06-10 | 2004-12-15 | Pliva - Lachema, A. S. | Stabilizovaná farmaceutická kompozice na bázi polyoxyethylovaného ricinového oleje a způsob její přípravy |
| US20040033959A1 (en) * | 2002-07-19 | 2004-02-19 | Boehringer Ingelheim Pharmaceuticals, Inc. | Pharmaceutical compositions for hepatitis C viral protease inhibitors |
| US20050075279A1 (en) | 2002-10-25 | 2005-04-07 | Boehringer Ingelheim International Gmbh | Macrocyclic peptides active against the hepatitis C virus |
| UY28240A1 (es) | 2003-03-27 | 2004-11-08 | Boehringer Ingelheim Pharma | Fases cristalinas de un potente inhibidor de la hcv |
| BRPI0409068A (pt) | 2003-04-02 | 2006-03-28 | Boehringer Ingelheim Int | composições farmacêuticas para inibidores de protease viral de hepatite c. |
| DE602004010137T2 (de) * | 2003-05-21 | 2008-09-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verbindungen als hepatitis c inhibitoren |
| AU2004274051A1 (en) | 2003-09-22 | 2005-03-31 | Boehringer Ingelheim International Gmbh | Macrocyclic peptides active against the hepatitis C virus |
| MXPA06010389A (es) | 2004-03-15 | 2007-01-19 | Boehringer Ingelheim Int | Procedimiento para preparar dipeptidos macrociclicos los cuales son adecuados para el tratamiento de infecciones virales de hepatitis c. |
| WO2005095403A2 (en) | 2004-03-30 | 2005-10-13 | Intermune, Inc. | Macrocyclic compounds as inhibitors of viral replication |
| JP5156374B2 (ja) | 2004-05-25 | 2013-03-06 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 非環式ｈｃｖプロテアーゼインヒビターの調製方法 |
| US20060276406A1 (en) | 2005-06-02 | 2006-12-07 | Schering Corporation | Methods of treating hepatitis C virus |
| EP2250174B1 (en) | 2008-02-04 | 2013-08-28 | IDENIX Pharmaceuticals, Inc. | Macrocyclic serine protease inhibitors |
| HRP20140666T1 (hr) | 2008-09-16 | 2014-10-10 | Boehringer Ingelheim International Gmbh | Kristalni oblici derivata 2-tiazolil-4-kinolinil-oksi, snažnog hcv-inhibitora |
| PE20120032A1 (es) | 2008-11-21 | 2012-02-12 | Boehringer Ingelheim Int | Composicion farmaceutica oral de un derivado de n-[4-(8-bromo-7-metoxiquinolin-2-il)-1,3-tiazol-2-il]-2-metilpropanamida |
| MA33491B1 (fr) | 2009-07-07 | 2012-08-01 | Boehringer Ingelheim Int | Composition pharmaceutique pour un inhibiteur de protease virale de l'hépatite c |
-
2010
- 2010-07-01 MA MA34511A patent/MA33491B1/fr unknown
- 2010-07-01 UA UAA201201066A patent/UA104195C2/ru unknown
- 2010-07-01 AP AP2011005979A patent/AP2011005979A0/xx unknown
- 2010-07-01 EA EA201200096A patent/EA023433B1/ru not_active IP Right Cessation
- 2010-07-01 PE PE2011002086A patent/PE20120322A1/es active IP Right Grant
- 2010-07-01 SG SG2012001368A patent/SG177569A1/en unknown
- 2010-07-01 JP JP2012519597A patent/JP5607736B2/ja not_active Expired - Fee Related
- 2010-07-01 DK DK10731685.3T patent/DK2451438T3/da active
- 2010-07-01 PT PT107316853T patent/PT2451438E/pt unknown
- 2010-07-01 HR HRP20140445AT patent/HRP20140445T1/hr unknown
- 2010-07-01 WO PCT/US2010/040734 patent/WO2011005646A2/en not_active Ceased
- 2010-07-01 GE GEAP201012562A patent/GEP20146016B/en unknown
- 2010-07-01 KR KR1020127000354A patent/KR101685941B1/ko not_active Expired - Fee Related
- 2010-07-01 CN CN201080030433.1A patent/CN102470103B/zh not_active Expired - Fee Related
- 2010-07-01 ME MEP-2014-23A patent/ME01718B/me unknown
- 2010-07-01 RS RS20140116A patent/RS53209B/sr unknown
- 2010-07-01 AU AU2010270783A patent/AU2010270783B2/en not_active Ceased
- 2010-07-01 SI SI201030565T patent/SI2451438T1/sl unknown
- 2010-07-01 MY MYPI2012000028A patent/MY154683A/en unknown
- 2010-07-01 EP EP10731685.3A patent/EP2451438B8/en active Active
- 2010-07-01 ES ES10731685.3T patent/ES2464367T3/es active Active
- 2010-07-01 BR BR112012000287A patent/BR112012000287B8/pt not_active IP Right Cessation
- 2010-07-01 NZ NZ596928A patent/NZ596928A/xx not_active IP Right Cessation
- 2010-07-01 CA CA2767692A patent/CA2767692C/en not_active Expired - Fee Related
- 2010-07-01 PL PL10731685T patent/PL2451438T3/pl unknown
- 2010-07-01 MX MX2011013824A patent/MX2011013824A/es active IP Right Grant
- 2010-07-05 UY UY0001032760A patent/UY32760A/es not_active Application Discontinuation
- 2010-07-06 TW TW099122196A patent/TWI490216B/zh not_active IP Right Cessation
- 2010-07-06 US US12/830,771 patent/US9034831B2/en active Active
- 2010-07-06 AR ARP100102427A patent/AR077393A1/es not_active Application Discontinuation
-
2011
- 2011-11-02 IL IL216098A patent/IL216098A/en active IP Right Grant
- 2011-12-29 CO CO11181070A patent/CO6480980A2/es not_active Application Discontinuation
-
2012
- 2012-01-05 TN TNP2012000009A patent/TN2012000009A1/en unknown
- 2012-01-06 CL CL2012000054A patent/CL2012000054A1/es unknown
- 2012-01-26 EC EC2012011624A patent/ECSP12011624A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP12011624A (es) | Composición Farmacéutica para un Inhibidor de Proteasa del Virus de la Hepatitis C. | |
| CO6361900A2 (es) | Composicion farmaceutica de un potente de hcv para su administración oral | |
| CO6491048A2 (es) | Inhibidores de la replicación de los virus de la gripe | |
| AR076388A1 (es) | Procedimientos para mejorar la farmocinetica | |
| MX2014002171A (es) | Tratamientos de combinacion para hepatitis c. | |
| CO6561788A2 (es) | Inhibidores del virus de la hepatitis c | |
| ECSP14013189A (es) | Inhibidores de la replicación de los virus de la gripe | |
| CL2012000919A1 (es) | Composicion que comprende un compuesto derivado de metoxicarbonil-amino-metilbutanoil-pirrolidinil-imidazol de formula i, inhibidor especifico de ns5a de hcv, y un compuesto derivado de oxo-pirrolidin-quinoleina de formula ii, inhibidor de proteasa ns3 de hcv; y uso en el tratamiento de la hepatitis c. | |
| CO6761335A2 (es) | Inhibidores del virus de la hepatitis c | |
| CL2011000145A1 (es) | Compuesto macrociclico derivado de quinoxalina y sus sales; inhibidor de la proteasa ns3 del virus de la hepatitis c(hcv); composicion farmaceutica que lo comprende; y uso en la prevencion o el tratamiento de una infeccion por hcv. | |
| CO6450600A2 (es) | Inhibidores de anillo fusionado de hepatitis c | |
| AR084393A1 (es) | Metodos para tratar el virus de la hepatitis c, composicion, uso, combinacion, kit y uno o mas compuestos anti vhc | |
| AR099632A1 (es) | Tratamiento de una infección viral de hepatitis c, que usa una combinación de compuestos | |
| CL2012001449A1 (es) | Uso de combinaciones del compuesto n-[(ciclopentiloxi)carbonil]-3-metil-l-valiol-(4r)-4-({8-bromo-2-[2-(isobutirilamino)-1,3-tiazol-4-il]-7-metoxi-4-quinolinil}oxi)-n-[(1r,2s)-1-carboxi-2-vinilciclopropil]-l-prolinamida; y envase que comprende las formas de dosificacion. | |
| AR086356A1 (es) | Combinacion farmaceutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2 | |
| CL2013003229A1 (es) | Compuestos inhibidores del virus de la hepatitis c (vhc); composicion farmaceutica que los comprende; y uso en el tratamiento de una infeccion por vhc. | |
| AR077138A1 (es) | Composiciones farmaceuticas utiles para tratar el vhc | |
| CL2013000670A1 (es) | Metodo para tratar una infeccion por virus de la hepatitis c (hcv) que comprende admninistrar un inhibidor de la serina proteasa ns3 del hvc, un inhibidor de la arn polimerasa dependiente de arn ns5b de hcv y opcionalmente ribavirina; composicion farmaceutica; estuche; y su uso de para el tratamiento de una infeccion por hcv. | |
| MX2021008432A (es) | Composiciones farmaceuticas y usos dirigidos a los trastornos del almacenamiento lisosomal. | |
| UY32600A (es) | Formulación en lípidos de un promotor de la apoptosis | |
| AR095538A1 (es) | Composiciones farmacéuticas de ésteres de testosterona de cadena larga lipoequilibrados para la administración oral | |
| AR083337A1 (es) | Tratamientos de infeccion por el virus de hepatitis c | |
| AR083780A1 (es) | Composicion farmaceutica para tratar infecciones del hcv | |
| MX2017009853A (es) | Prevencion o tratamiento de enfermedades urinarias o gotosas. | |
| CY1115027T1 (el) | Φαρμακευτικη συνθεση για αναστολεα ιικης πρωτεασης ηπατιτιδας c |